Wikipedia

List of antidepressants

This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses. All drugs listed are approved specifically for major depressive disorder unless noted otherwise.

Selective serotonin reuptake inhibitors (SSRIs)

edit

Selective serotonin reuptake inhibitors include:

Discontinued/withdrawn

edit

Serotonin–norepinephrine reuptake inhibitors (SNRIs)

edit

Serotonin–norepinephrine reuptake inhibitors include:

Serotonin–dopamine reuptake inhibitor (SDRIs)

edit

Serotonin–dopamine reuptake inhibitors include:

None currently marketed

Discontinued/withdrawn

edit

Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs)

edit

Serotonin–norepinephrine–dopamine reuptake inhibitors include:

Serotonin modulators and stimulators (SMSs)

edit

Serotonin modulators and stimulators include:

Serotonin antagonist and reuptake inhibitors (SARIs)

edit

Serotonin antagonist and reuptake inhibitors include:

  • Nefazodone (Dutonin, Nefadar, Serzone) – withdrawn/discontinued in most countries
  • Trazodone (Desyrel)

Discontinued/withdrawn

edit

Norepinephrine reuptake inhibitors (NRIs)

edit

Norepinephrine reuptake inhibitors include:

Off-label only

edit

Norepinephrine–dopamine reuptake inhibitors (NDRIs)

edit

Norepinephrine–dopamine reuptake inhibitors include:

Off-label only

edit

Discontinued/withdrawn

edit

Tricyclic antidepressants (TCAs)

edit

Tricyclic antidepressants include:

Opipramol (Insidon), tianeptine (Stablon, Coaxil) and amineptine (discontinued; formerly Survector, Maneon) are chemically TCAs but are pharmacodynamically atypical, and are therefore grouped elsewhere.

Discontinued/withdrawn

edit

Tetracyclic antidepressants (TeCAs)

edit

Tetracyclic antidepressants include:

Mianserin, mirtazapine, and setiptiline are also sometimes described as noradrenergic and specific serotonergic antidepressants (NaSSAs).

Monoamine oxidase inhibitors (MAOIs)

edit

Monoamine oxidase inhibitors include

Irreversible

edit

Non-selective

edit

Discontinued/withdrawn

Selective for MAO-B

edit

Reversible

edit

Non-selective

edit

Discontinued/withdrawn

Selective for MAO-A

edit

These drugs are sometimes described as reversible inhibitors of MAO-A (RIMAs).

Discontinued/withdrawn

Mixed

edit

Non-selective

edit
  • Bifemelane (Alnert, Celeport) – RIMA, irreversible inhibitor of MAO-B, and weak NRI

Atypical antipsychotics

edit

Atypical antipsychotics include:

Others

edit

Marketed

edit

Off-label only

edit

Discontinued/withdrawn

edit

Over-the-counter

edit

The following antidepressants are available both with a prescription and over-the-counter:

Adjunctive treatments

edit

Atypical antipsychotics

edit

Atypical antipsychotics include:

  • Aripiprazole (Abilify) – approved as an adjunct to antidepressant for major depression
  • Brexpiprazole (Rexulti) – approved as an adjunct to antidepressant for major depression
  • Lumateperone (Caplyta) – approved as an adjunct to mood stabilizer for bipolar depression
  • Lurasidone (Latuda) – approved as an adjunct to mood stabilizer for bipolar depression
  • Olanzapine (Zyprexa) – approved as an adjunct to antidepressant for major depression
  • Quetiapine (Seroquel) – approved as an adjunct to antidepressant or mood stabilizer for major depression and bipolar depression

Off-label only

edit

Typical antipsychotics

edit

Typical antipsychotics include:

None currently approved

Off-label only

edit

Dopamine reuptake inhibitor

edit

Dopamine reuptake inhibitors include:

None currently approved

Off-label only

edit

Others

edit

Off-label only

edit

Combination products

edit

See also

edit

References

edit
  1. ^ Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
  2. ^ Fedder D, Patel H, Saadabadi A (March 2023). "Atomoxetine". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 29630286.
  3. ^ Dell'Osso B, Palazzo MC, Oldani L, Altamura AC (December 2011). "The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects". CNS Neurosci Ther. 17 (6): 723–32. doi:10.1111/j.1755-5949.2010.00217.x. PMC 6493872. PMID 21155988.
  4. ^ Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, et al. (2009). "A systematic review of augmentation strategies for patients with major depressive disorder". Psychopharmacol Bull. 42 (3): 57–90. PMID 19752841.
  5. ^ a b Corp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". J Clin Psychiatry. 75 (9): 1010–8. doi:10.4088/JCP.13r08851. PMID 25295426.
  6. ^ Arias HR, Santamaría A, Ali SF (2009). "Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion". Int. Rev. Neurobiol. International Review of Neurobiology. 88: 223–55. doi:10.1016/S0074-7742(09)88009-4. ISBN 9780123745040. PMID 19897080.
  7. ^ Dale E, Bang-Andersen B, Sánchez C (2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs". Biochem. Pharmacol. 95 (2): 81–97. doi:10.1016/j.bcp.2015.03.011. PMID 25813654.
  8. ^ Challman TD, Lipsky JJ (2000). "Methylphenidate: its pharmacology and uses". Mayo Clin. Proc. 75 (7): 711–21. doi:10.4065/75.7.711. PMID 10907387.
  9. ^ Prommer E (2012). "Methylphenidate: established and expanding roles in symptom management". Am J Hosp Palliat Care. 29 (6): 483–90. doi:10.1177/1049909111427029. PMID 22144657. S2CID 21384037.
  10. ^ "Amisulpride". AdisInsight. 24 October 2021. Retrieved 22 October 2024.
  11. ^ "Levosulpiride". AdisInsight. 24 October 2021. Retrieved 22 October 2024.
  12. ^ "Kusuri-no-Shiori(Drug Information Sheet)". くすりの適正使用協議会. Retrieved 22 October 2024.
  13. ^ "SPRAVATO™ (esketamine) nasal spray FDA label" (PDF). Food and Drug Administration. 5 March 2019. Retrieved 6 March 2019.
  14. ^ Zhang MW, Harris KM, Ho RC (2016). "Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications". BMC Med Ethics. 17: 4. doi:10.1186/s12910-016-0087-3. PMC 4714497. PMID 26768892.
  15. ^ Thase ME (2016). "Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?". Psychiatr. Clin. North Am. 39 (3): 477–86. doi:10.1016/j.psc.2016.04.008. PMID 27514300.
  16. ^ Urban AE, Cubała WJ (February 2020). "The role of eugeroics in the treatment of affective disorders". Psychiatr Pol. 54 (1): 21–33. doi:10.12740/PP/OnlineFirst/90687. PMID 32447354.
  17. ^ Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S (May 2017). "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". Eur Neuropsychopharmacol. 27 (5): 423–441. doi:10.1016/j.euroneuro.2017.03.003. PMID 28318897. S2CID 3740987.
  18. ^ Nunez NA, Singh B, Romo-Nava F, Joseph B, Veldic M, Cuellar-Barboza A, et al. (March 2020). "Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials". Bipolar Disord. 22 (2): 109–120. doi:10.1111/bdi.12859. PMID 31643130.
  19. ^ Szmulewicz AG, Angriman F, Samamé C, Ferraris A, Vigo D, Strejilevich SA (June 2017). "Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis". Acta Psychiatr Scand. 135 (6): 527–538. doi:10.1111/acps.12712. PMID 28256707. S2CID 3712257.
Retrieved from "https://en.wikipedia.org/w/index.php?title=List_of_antidepressants&oldid=1258111613"